An increased activation of GPC3-specific T cells and significantly reduced hepatocellular carcinoma growth were observed in MSCsGPC3-CD3-treated tumor-bearing mice, demonstrating the therapeutic potential of MSCsGPC3-CD3 in the immunotherapy of hepatocellular carcinoma [34]. This evidence concerns the gene GPC3 and hepatocellular carcinoma.